Pregnant Participants with MS and Exposure to BRIUMVI®
A study is being planned to compare the rates of major congenital malformations among pregnant participants with multiple sclerosis (MS) who are either exposed to the medication BRIUMVI® or unexposed. The study aims to follow participants for up to 52 weeks post-delivery.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
Why it matters
Understanding the impact of BRIUMVI® exposure during pregnancy on congenital malformations is crucial for the health of both mothers and babies. It may inform healthcare decisions for women with MS.
What this does not prove
No actual results are available yet, as the study is in the planning stages. The absence of results means no conclusions can be drawn about the specific effects of BRIUMVI® on congenital malformations at this time.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
Supporting passages (5)
subjectsstudy population will include pregnant participants with MS who are either exposed or not exposed to BRIUMVI®.
primary endpoint"measure": "Percentage of Participants with Major Congenital Malformations (MCMs)",
follow up"timeFrame": "Up to 52 weeks post-delivery"
findings"briefSummary": "The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®."
limitationsNo results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.